Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies - PubMed (original) (raw)

Review

Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies

A J Murgo. Oncologist. 2001.

Free article

Abstract

Arsenic trioxide inhibits growth and promotes apoptosis in many different cancer cell lines. The National Cancer Institute is working cooperatively with research centers across the U.S. to evaluate its clinical activity in hematologic malignancies, such as acute promyelocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, chronic lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. It is also supporting research in solid tumors, such as advanced hormone-refractory prostate cancer and renal cell cancer and in cervical cancer and refractory transitional cell carcinoma of the bladder. The safety and pharmacokinetics of arsenic trioxide are also being evaluated in pediatric patients with refractory leukemia and lymphoma. The results of these ongoing studies should provide important insights into the clinical utility of arsenic trioxide in these diseases.

PubMed Disclaimer

Cited by

Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intraarterial versus intravenous administration.
Seong NJ, Yoon CJ, Kang SG, Chung JW, Kim HC, Park JH. Seong NJ, et al. Korean J Radiol. 2012 Mar-Apr;13(2):195-201. doi: 10.3348/kjr.2012.13.2.195. Epub 2012 Mar 7. Korean J Radiol. 2012. PMID: 22438687 Free PMC article.
Erythrocyte Membrane-Coated Arsenic Trioxide-Loaded Sodium Alginate Nanoparticles for Tumor Therapy.
Lian Y, Wang X, Guo P, Li Y, Raza F, Su J, Qiu M. Lian Y, et al. Pharmaceutics. 2019 Dec 24;12(1):21. doi: 10.3390/pharmaceutics12010021. Pharmaceutics. 2019. PMID: 31878155 Free PMC article.
Sevelamer arsenite nanoparticle as a Pi-responsive drug carrier and embolic agent for chemoembolization.
Bi QC, Tang JJ, Zhao J, Lv YF, Deng ZQ, Chen H, Xu YH, Xie CS, Liang QR, Luo RG, Tang Q. Bi QC, et al. Drug Deliv. 2022 Dec;29(1):1447-1456. doi: 10.1080/10717544.2022.2072541. Drug Deliv. 2022. PMID: 35532152 Free PMC article.
Natural variation in C. elegans arsenic toxicity is explained by differences in branched chain amino acid metabolism.
Zdraljevic S, Fox BW, Strand C, Panda O, Tenjo FJ, Brady SC, Crombie TA, Doench JG, Schroeder FC, Andersen EC. Zdraljevic S, et al. Elife. 2019 Apr 8;8:e40260. doi: 10.7554/eLife.40260. Elife. 2019. PMID: 30958264 Free PMC article.
Arsenic trioxide: insights into its evolution to an anticancer agent.
Hoonjan M, Jadhav V, Bhatt P. Hoonjan M, et al. J Biol Inorg Chem. 2018 May;23(3):313-329. doi: 10.1007/s00775-018-1537-9. Epub 2018 Feb 2. J Biol Inorg Chem. 2018. PMID: 29396610 Review.

Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies - PubMed (original) (raw)